{
  "id": 16642606,
  "title": "Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results",
  "url": "https://urgent.news/2026/10/26/immunotherapy-combo-extends-survival-for-patients-with-aggressive",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T18:20:06.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-immunotherapy-combo-survival-patients-aggressive.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter,…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}